Pembrolizumab Plus Olaparib for Patients with Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: the Randomized, Open-Label, Phase III KEYLYNK-010 Trial.Emmanuel S. Antonarakis,Se Hoon Park,Jeffrey C. Goh,Sang Joon Shin, Jae Lyun Lee,Niven Mehra,Ray McDermott, Nuria Sala-Gonzalez,Peter C. Fong,Richard Greil,Margitta Retz,Juan Pablo Sade, Patricio Yanez, Yi-Hsiu Huang,Stephen D. Begbie,Rustem Airatovich Gafanov, Maria De Santis,Eli Rosenbaum,Michael P. Kolinsky,Felipe Rey, Kun-Yuan Chiu, Guilhem Roubaud,Gero Kramer, Makoto Sumitomo, Francesco Massari,Hiroyoshi Suzuki, Ping Qiu,Jinchun Zhang,Jeri Kim,Christian H. Poehlein,Evan Y. YuJOURNAL OF CLINICAL ONCOLOGY（2023）引用 3|浏览10关键词Metastatic Prostate Cancer,Prostate CancerAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
